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Abstract: Clear cell renal cell carcinoma (ccRCC) is the most common and lethal form of urological
cancer diagnosed globally. Mutations of the von Hippel-Lindau (VHL) tumor-suppressor gene and
the resultant overexpression of hypoxia-inducible factor (HIF)-1α protein are considered hallmarks
of ccRCC. Persistently activated HIF-1α is associated with increased cell proliferation, angiogenesis,
and epithelial–mesenchymal transition (EMT), consequently leading to ccRCC progression and
metastasis to other organs. However, the VHL status alone cannot predict the differential sensitivity
of ccRCC to cancer treatments, which suggests that other molecular differences may contribute
to the differential response of ccRCC cells to drug therapies. In this study, we investigated the
response to metformin (an antidiabetic drug) of two human ccRCC cell lines Caki-1 and Caki-2, which
express wild-type VHL. Our findings demonstrate a differential response between the two ccRCC cell
lines studied, with Caki-2 cells being more sensitive to metformin compared to Caki-1 cells, which
could be linked to the differential expression of HIF-1α despite both cell lines carrying a wild-type
VHL. Our study unveils the therapeutic potential of metformin to inhibit the progression of ccRCC
in vitro. Additional preclinical and clinical studies are required to ascertain the therapeutic efficacy
of metformin against ccRCC.
Keywords: renal cell carcinoma; von Hippel-Lindau; hypoxia-inducible factor; AMP-activated
kinase; metformin
1. Introduction
Renal cell carcinoma (RCC) is the third most common urological cancer and the sixth leading
cause of cancer deaths in the United States [1–4]. The renal cancer cells are extremely proliferative and
metastatic, and account for 3.8% of all new cancers [1,3]. Clear cell renal cell carcinoma (ccRCC) is the
most common subtype of RCC and accounts for approximately 70–75% of all cases [5]. For localized
ccRCC, surgical resection continues to be a curative treatment option [6–8]. However, for the
management of recurrent or metastatic ccRCC, targeted drug therapy is preferred; this includes the use
of tyrosine kinase inhibitors such as sunitinib, sorafenib, axitinib and pazopanib; mammalian target of
rapamycin (mTOR) inhibitors such as temsirolimus and everolimus; and monoclonal antibodies such
as bevacizumab, which targets vascular endothelial growth factor (VEGF) [9,10]. In addition to tyrosine
kinase inhibitors, immunotherapy using nivolumab and interferon-α are considered to be the standard
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treatment strategies [11,12]. However, ccRCC gradually develops resistance to chemotherapy and
other treatment modalities such as hormonal therapy and radiotherapy; hence, there is a tremendous
need for the advancement of new therapeutic alternatives [13].
Mutation of the von Hippel-Lindau (VHL) tumor suppressor gene and the resultant overexpression
of hypoxia-inducible factor (HIF)-1α protein are considered hallmarks of ccRCC [8,14]. Persistently
activated HIF-1α is associated with cell proliferation, angiogenesis, and epithelial–mesenchymal
transition (EMT), consequently leading to ccRCC progression and metastasis to other organs [6,8].
Several cell lines have been used to model ccRCC in research with some expressing wild-type VHL, and
others characterized by a loss-of-function mutation in VHL [15]. The VHL status has been reported in
several studies to affect the sensitivity of ccRCC cells to various drug therapies; however, multiple lines
of evidence suggest that other molecular differences may also contribute to the differential sensitivity of
RCC cells to drugs [16–18]. In this study, we focused on investigating some of the molecular differences
between two major cell lines used in ccRCC, namely Caki-1 and Caki-2. Both Caki-1 and Caki-2 cells
are primarily defined as human ccRCC cell lines; however, Caki-1 cell lines are metastatic ccRCC,
harboring wild-type VHL, whereas, Caki-2 cell lines are considered as ccRCC expressing wild-type
von Hippel-Lindau protein (pVHL) [15].
Metformin, an activator of the AMP-activated kinase (AMPK), is primarily prescribed for the
management of type-2 diabetes. Specifically, metformin acts through inhibiting gluconeogenesis
(glucose production) in the liver via activation of AMPK signaling in hepatocytes [19]. In addition,
metformin also inhibits pyruvate dehydrogenase activity and mitochondrial respiration, which in
turn increases the theoretical risk of lactic acidosis in cells [19]. Nevertheless, the incidence of lactic
acidosis is rare and is observed mainly in patients with severe renal dysfunction [19,20]. Thus, a lower
dose of metformin is recommended in diabetic patients with moderate kidney disease, and the use
of metformin is contraindicated in patients with advanced kidney disease [19,20]. Emerging studies
suggest that metformin exerts antineoplastic effects in various types of cancers, such as cancers of
the breast, colon, liver, prostate, and kidney [21–23]. Although the activation of AMPK by metformin
has been shown to decrease the expression of HIF-1α and mTOR activation in some cancers and in
diabetic rat kidneys [23–25], comprehensive signaling pathways exerted by metformin to inhibit cell
proliferation, cell cycle arrest and apoptosis in ccRCC are yet to be thoroughly investigated.
Work by Xu et al. [26] found that the downregulation of HIF-1α by small hairpin RNA
(shRNA) inhibited cell growth, migration, and invasion in Caki-2 and OS-RC-2 cells, and suppressed
tumorigenicity in a xenograft mouse model. Similarly, Kondo et al. [27] reported that the
downregulation of HIF-2α using shRNA in 786-O and A498 cells inhibited their tumorigenicity
in a xenograft mouse model.
Intriguingly, Raval et al. [17] demonstrated contrasting properties of HIF-1α and HIF-2α in
VHL-defective ccRCC cells, with HIF-1α inhibiting and HIF-2α promoting cell growth. Conversely,
Gudas et al. [28] reviewed the evidence available from human ccRCC cell lines, human ccRCC
specimens, murine models, and mouse xenograft models, and reported a convergence of both clinical
and theoretical data highlighting the significant role of HIF-1α in promoting ccRCC. Furthermore, the
authors noted that ccRCC is a highly heterogeneous disease, the exact roles of HIF-1α and HIF-2α are
incomplete, and further research needs to focus on determining their diverse role in ccRCC. Altogether,
these previous studies highlight the complexity of ccRCC and the need for further dissection of the
signaling pathways involved in ccRCC tumorigenesis and survival. The VHL gene is often mutated
in ccRCC cell lines (e.g., 786-O and UM-RC-2) with subsequent activation of the HIF pathway that
regulates the expression of various target proteins involved in ccRCC progression; however, the status
of VHL alone cannot predict the differential sensitivity of ccRCC to cancer treatments. Therefore, it
is believed that other molecular differences may contribute to the differential response of these cells
to drug therapies. Thus, it is of paramount importance to decipher the critical molecular pathways
contributing to ccRCC progression.
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Liu et al. [3] observed that metformin effectively induced G0/G1 cell phase arrest and suppressed
cell growth in 786-O and OS-RC-2 cell lines, and an in vivo murine model of RCC. Similarly,
Kalogirou et al. [29] revealed that Caki-1 cells were less sensitive towards metformin treatment
in comparison to Caki-2 cells, and that the sensitivity of metformin was associated with microRNA-21
(miR-21)/phosphatase and tensin homolog (PTEN) tumor suppressor expression in both Caki-1 and
Caki-2 cells. Although accumulating evidence suggests that metformin inhibits cell proliferation
in some cancers, the precise mechanism(s) exerted by metformin to inhibit the growth of ccRCC
remain(s) unclear and yet to be fully elucidated. Therefore, the aim of this work was to investigate
the antineoplastic effect of metformin against ccRCC cell lines, namely Caki-1 and Caki-2, and to
explore if there is a differential selectivity in the VHL status of these two cell lines by evaluating
HIF-1α and HIF-2α expression. In addition, we aimed to explore other critical downstream targets
and their possible underlying signaling mechanisms contributing to the progression of ccRCC such as
phosphoinositide 3-kinase (PI3K)/AKT/mTOR, autophagy, and Wnt/β-catenin pathways, and assess
any possible differential activation of these signaling hubs between Caki-1 and Caki-2 cells.
2. Materials and Methods
2.1. Reagents
Metformin (1,1-dimethylbiguanide hydrochloride) was purchased from Sigma-Aldrich (St. Louis,
MO, USA) and phosphate-buffered saline (PBS) (Gibco, Grand Island, NY, USA) was used
to solubilize it. The various concentrations of metformin used were 1, 2, 5, 10, 20, and
50 mM diluted in culture media. McCoy’s 5A (modified) medium, fetal bovine serum
(FBS), 0.25% Trypsin– ethylenediaminetetraacetic acid (EDTA) solution, penicillin/streptomycin
(10,000 U/mL) were purchased from Gibco. Alamar Blue™ cell viability reagent and Tali™ cell
cycle kit were purchased from Thermo-Fisher Scientific (Eugene, OR, USA). Antibodies used
for Western blot analysis were procured from the following sources: HIF-1α, phospho-AMPK
(Thr172), phospho-mTOR (Ser2448), phospho-Akt (Ser473), α-SMA, LC3-II, phospho-PTEN(Ser380),
phospho-GSK-3β (Ser9), Wnt3a, phospho-LRP6 (Ser1490), phospho-β-Catenin (Ser33/37/Thr41),
and horseradish peroxidase-conjugated secondary antibodies were purchased from Cell Signaling
Technology (Danvers, MA, USA), and β-actin antibody was from Abcam (Cambridge, MA, USA).
For flow cytometry analysis, fluorescein isothiocyanate (FITC)-labeled annexin V and propidium
iodide (PI) staining solution were purchased from BD Biosciences (San Jose, CA, USA) and Cyto-ID®
autophagy detection kit from Enzo Life Sciences, Inc. (Farmingdale, NY, USA). All other reagents were
purchased from Sigma-Aldrich unless otherwise specified.
2.2. Cell Lines and Culture Conditions
The human ccRCC cell lines, Caki-1 (ATCC® HTB-46™) and Caki-2 (ATCC® HTB-47™)
were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were
maintained in McCoy’s 5A (modified) medium supplemented with 10% FBS, 1% L-glutamine and 1%
penicillin/streptomycin. Cells were cultured in a 37 ◦C humidified atmosphere containing 5% CO2
and 95% air. All methods were conducted in accordance with the relevant guidelines and regulations
of the institutional biosafety committee.
2.3. Cell Viability Assay
Cells were seeded at a density of 2× 105 cells per well in 6-well plates and incubated in complete
medium. Next day, cells were either left untreated (control) or incubated with various concentrations
of metformin (1, 2, 5, 10, 20, and 50 mM) for a further period of 48 h. A cell proliferation assay was then
performed using Alamar Blue™ reagent according to the manufacturer’s recommendations. Alamar
Blue™ stock solution was added at a ratio of 1:50 in the culture medium, and then cells were incubated
for 4 h protected from direct light. Fluorescence was then read with 544 nm excitation and 590 nm
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emission wavelengths using a Synergy H1 microplate reader (BioTek Instruments, Winooski, VT, USA).
Cell viability was assessed by fluorescence and values were normalized to control and expressed as
the percentage of control as mean ± standard error of the mean (SEM).
2.4. Cell Cycle Analysis
Cells were seeded at the density of 2× 105 per well in 6-well plates. The next day, cells were either
left untreated or incubated with metformin (concentrations ranging from 1 to 50 mM) for a period of
48 h. Cell cycle progression analysis was then performed using the Tali TM cell cycle assay protocol
following the manufacturer guidelines. Briefly, cells were trypsinized, centrifuged and resuspended
in PBS. Suspended cells were then fixed with 70% ice-cold ethanol and placed at −20 ◦C overnight.
The following day, cells were stained with 200 µL of Tali TM cell cycle solution and incubated at room
temperature for 30 min in the dark before being analyzed using a TaliTM image-based cytometer
(Life Technologies, Paisley, UK).
2.5. Detection of Apoptosis
The annexin V-FITC apoptosis detection kit was used to assess apoptosis in both Caki-1 and Caki-2
cell lines. Briefly, cells were seeded at the density of 2× 105 cells/well in 6-well plates. The following
day, cells were treated with various concentrations of metformin (2, 5, 10, 20, and 50 mM) for a further
period of 48 h. Then, the supernatant was collected, and cells were trypsinized and suspended in
1× annexin V binding buffer at a concentration of 1 × 106 cells/mL. Following this, 5 µL of annexin V
and 2 µL of PI were added to the suspension of cells (100 µL containing 1 × 105 cells). The suspension
was then vortexed gently and incubated for 30 min at room temperature in the dark before being
analyzed by flow cytometry using a BD LSR Fortessa cell analyzerTM system (BD Biosciences, San Jose,
CA, USA).
2.6. In Vitro Scratch Migration Assay
The in vitro scratch migration assay was performed to quantify the rate of cell migration and was
performed as described by Hulkower and Herber [30]. Briefly, cells were seeded in a 6-well culture
plate at the density of 2× 105 cells/well and kept in the CO2 incubator. The next day, using a sterile
200 µL pipette tip, a thin scratch was made through the confluent monolayer of cells, and carefully the
old culture medium and cell debris were aspirated. Cells were replenished with fresh medium. Finally,
images were captured using optika vision image analyzer (Optika Srl, Via Rigla, Ponteranica, Italy) before
and after metformin treatment (5, 10, 20, and 50 mM) at the following time points: 0, 6, and 24 h. The
values were expressed as the percentage (%) of gap reduction compared to baseline (at 0 h time point).
2.7. Assessment of Autophagy
The Cyto-ID® autophagy detection kit was used to monitor autophagy in both Caki-1 and Caki-2
cell lines. Briefly, cells were seeded at the density of 2× 105 cells/well in 6-well plates. The next day,
cells were left untreated or incubated with various concentrations of metformin (10, 20 and 50 mM).
After 48 h of drug treatment, cells were washed with PBS and incubated with a master-mix solution
containing Cyto-ID® green autophagy detection dye (1:1000), Hoechst 33342 (1 µM) and 5% FBS for
30 minutes at 37 ◦C. Then, cells were washed and immediately analyzed by flow cytometry using a BD
LSR Fortessa cell analyzerTM system.
2.8. Western Blot Analysis
Western blotting was performed as described previously [31] to assess the effects of metformin
on the expression of critical proteins involved in various signaling pathways such as AMPK,
PTEN, AKT/mTOR, HIF-1α pathway, autophagy (light chain 3 (LC3)), EMT marker α-smooth
muscle actin (α-SMA) and Wnt/β-catenin signaling pathway. Briefly, after 48 h of metformin
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treatment, the whole-cell lysate was collected in sodium dodecyl sulfate (SDS) sample lysis buffer
(0.5 M Tris pH 6.8, 20% SDS and a cocktail of protease and phosphatase inhibitors) followed by
sonication. Protein concentrations were determined in samples using the bicinchoninic acid assay
(BCA). An equal amount of proteins (30 µg) were then loaded and separated on sodium dodecyl
sulfate–polyacrylamide (SDS–PAGE) gels and later transferred to a polyvinylidene difluoride (PVDF)
membrane. After blocking, blots were incubated overnight with respective primary antibodies
(Cell Signaling Technology), washed three times with a mixture of Tris-buffered saline (TBS) and
polysorbate 20 (T-TBS), and then incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies (Cell Signaling Technology) for 1 h. Enhanced chemiluminescence (ECL) reagent
(Abcam) was used to visualize the proteins bands using FlourChemTM M system (ProteinSimple,
San Jose, CA, USA). The AlphaView software (Protein Simple, San Jose, CA, USA) was used to quantify
protein band intensities.
2.9. Statistical Analysis
The results were expressed as the mean ± SEM. One-way or two-way analysis of variance
(ANOVA) tests, as appropriate, followed by Tukey’s or Bonferroni multiple comparisons post-hoc tests
were performed using Prism 7 (GraphPad, San Diego, CA, USA) to compare the groups. P < 0.05 was
considered to be statistically significant.
3. Results
3.1. Metformin Causes a Reduction in Cell Viability in both Caki-1 and Caki-2 Cell Lines
Cell proliferation is an integral part of tumor promotion and progression, and it manifests with
the altered expression of various proteins [32]. Thus, to investigate whether metformin could inhibit
cell growth in ccRCC, both Caki-1 and Caki-2 cell lines were incubated in the absence and presence of
metformin (1–50 mM) for a period of 48 h. As shown in Figure 1A, no major changes in cell viability
were observed in metformin-treated Caki-1 cells up to the concentration of 10 mM (92 % of cells were
still viable); however, a significant dose-dependent decrease in cell viability was observed with higher
concentrations (20 mM and 50 mM (84% and 42% respectively)). Interestingly, metformin-treated
Caki-2 cells showed a significant and dose-dependent decrease in cell viability at all concentrations
except the lowest (i.e., 82% in 2 mM, 74% in 5 mM, 73% in 10 mM, 68% in 20 mM, and 23% in 50 mM)
as shown in Figure 1B. Altogether, our findings indicated a differential sensitivity of Caki-1 and Caki-2
cells to cell viability reduction caused by metformin, with Caki-2 being more sensitive to lower doses
of metformin.
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Figure 1. Metformin reduce ll iability in Caki-1 and Caki-2 ren l ancer cell lines. (A) Caki-1
and (B) Caki-2 cells were incubated in the absence (c ntrol) or presence of metformin (1, 2, 5, 10, 20,
and 50 mM) for 48 h. Cell viability w s analyzed using Alamar Blue™ assay, and the fluorescence
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mean ± SEM (n = 4–5 per group). * P < 0. 5; ** P < 0.001; and *** P < 0.0001 vs. control.
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3.2. Metformin Causes G0/G1 Phase Cell Cycle Arrest in Caki Cell Lines
A Tali TM cell cycle assay kit was used to determine the percentage of cells in each cell cycle
phase following exposure of ccRCC cells to varying concentrations of metformin for 48 h. As shown
in Figure 2A, no changes were observed with Caki-1 cells up to 20 mM of metformin with only 12%
in 2 mM, 14% in 5 mM, 15% in 10 mM, and 18% in 20 mM of cells displayed cell cycle arrest at
G0/G1; however, at the 50 mM dose, around 34% of cells showed substantial cell cycle arrest at G0/G1
compared to the control (7%). In contrast, Caki-2 cells demonstrated strong dose-dependent (5–50 mM)
cell cycle arrest at G0/G1 phase in the presence of metformin (i.e., 31% in 5 mM, 35% in 10 mM, 47%
in 20 mM, and 54% in 50 mM compared to 8% in the control group; Figure 2B). These results further
suggest that Caki-2 cells are more susceptible to the antiproliferative actions of metformin compared
with Caki-1 cells.
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Figure 2. Metformin-induced G0/G1 cell cycle arrest in Caki-1 and Caki-2 cells. Cell cycle progression
was analyzed in (A) Caki-1 and (B) Caki-2. Cells were incubated in the absence (control) or presence
of metformin (1, 2, 5, 10, 20, and 50 mM) for 48 h. Histograms represent the percentage of cells
measured at each of the different phases of the cell cycle in each treatment group. Data are presented
as mean ± SEM and were analyzed by two-way ANOVA, followed with Tukey’s multiple comparison
tests (n = 4–6 per group). * P < 0.05; ** P < 0.001; and *** P < 0.0001 vs. control.
3.3. Differential Apoptotic Response to Metformin Treatment in Caki-1 and Caki-2 Cells
It is well-documented that oncogenic mutations can disrupt apoptosis and deregulate apoptotic
signaling pathways, thereby enabling cancer cells to evade programmed cell death and subsequently
leading to uncontrolled cell growth and migration [33]. We investigated the impact of metformin
treatment on the induction of apoptosis in Caki-1 and Caki-2 cells. As depicted in Figure 3A,C,
metformin failed to induce apoptosis in Caki-1 cells up to 20 mM, and only the highest concentration
of metformin (i.e., 50 mM) caused a moderate induction of apoptosis (12%). However, a significant
and dose-dependent induction of apoptosis was observed in Caki-2 cells starting from 5 mM up to
50 mM (26%) compared to the control (Figure 3B,D). These data further support that Caki-2 cells were
more sensitive to the antineoplastic effects of metformin compared with Caki-1 cells.
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Figure 3. Metformin selectively induced a stronger a optotic response in Caki-2 cells compared to
Caki-1 cells. Flow cytometry nalysis of a optosis in (A,C) Caki-1 and (B,D) Caki-2. Cells were
incubated in the absence (control) or presence of metformin (1, 2, 5, 10, 20, and 50 mM) for 48 h,
and then apoptosis was determined by double labeling of cells with annexin V-FITC/propidium
iodide staining, followed by flow cytometry analysis. (C,D) Histograms represent pooled data from
four independent experiments per group. Data are presented as mean ± SEM. * P < 0.05; ** P < 0.001;
and *** P < 0.0001 vs. control.
3.4. Metformin Suppresses Migration of Both Caki-1 and Caki-2 Cells
The ability of cancer cells to metastasize is principally determined by the cells’ capability to
undergo changes and reorganize their morphology through processes, such as EMT, which confers
cancer cells increased migratory capacity and invasiveness, and promotes tumor metastasis [34].
Moreover, studies in surgically-resected renal tissues from patients with ccRCC revealed the existence
of cancer-associated fibroblasts, which can also promote tumor progression and metastasis through
various mechanisms including induction of EMT [35,36]. Thus, we quantified the effect of metformin
on cell migration rate using a scratch migration assay. We found that metformin treatment noticeably
inhibited the capacity of wound healing in both Caki-1 (Figure 4A,C) and Caki-2 cells (Figure 4B,D),
suggesting that metformin could effectively inhibit cell migration and invasion in both cell types
whereas untreated Caki-1 and Caki-2 cells (controls) demonstrated a higher capacity to migrate and
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invade (gap closed within 24 h). These data indicate that metformin treatment equally inhibited cancer
cell migration in both Caki-1 and Caki-2 cells.
α-SMA is a highly conserved protein involved in cell motility, structure and integrity. Moreover,
α-SMA is commonly used as a marker of myofibroblast differentiation, and it plays a substantial
role in cancer progression. Thus, we assessed the protein expression of α-SMA to decipher the
antimigratory effect of metformin in ccRCC. Interestingly, as depicted in Figure 4E,F, metformin caused
dose-dependent repression of α-SMA’s protein expression in both Caki-1 and Caki-2 cells. Intriguingly,
Caki-1 cells exhibited a more pronounced decrease in α-SMA’s protein expression, which was observed
with doses as low as 5 and 10 mM; whereas, in Caki-2 cells, the reduction of α-SMA’s expression was
observed with higher doses (10 mM) as shown in Figure 4F. From these findings, it is evident that
metformin was effective in blunting cell migration and reversing EMT in both Caki-1 and Caki-2 cells.
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Figure 4. Metformin inhibited cell migration and invasion in both Caki-1 and Caki-2 cells. In vitro 
scratch migration assay at 0, 6 and 24 h following metformin treatment (5, 10, 20, and 50 mM) are 
shown in (A) Caki-1 cells (B) and Caki-2 cells. Images are representative of three independent 
experiments in each group. Pooled quantified normalized data expressed as gap reduction 
(percentage of control) is presented for (C) Caki-1 and (D) Caki-2. (E) Western blot analysis of the 
expression of α-SMA in Caki-1 and Caki-2. Images are representative of n = 4–5 per group. (F) 
Histograms represent pooled densitometry data normalized to β-actin expressed as the percentage of 
control. Data are presented as mean ± SEM. *P < 0.05 vs. control. 
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The overexpression of HIF-1α protein has been shown to be involved in the development and 
progression of ccRCC due to mutations in the VHL gene [28]. Therefore, targeting HIF-1α protein 
might be a promising approach. To investigate whether metformin could affect the expression of HIF-
1α, Western blot analysis was performed in both cell lines in the absence and presence of metformin 
(2, 5, and 10 mM). Intriguingly, as shown in Figure 5A,B, there was no expression of HIF-1α protein 
with Caki-1 cells; however, Caki-2 cells expressed HIF-1α protein. Importantly, in the presence of 
metformin (10 mM), the protein expression of HIF-1α was reduced in Caki-2 cells compared to the 
control (Figure 5A). In addition, we also evaluated the expression of HIF-2α protein (data not shown); 
however, we did not observe any expression of this protein in both cell lines. These results showed 
that Caki-2 cells, which are known to express wild-type pVHL, expressed high levels of HIF-1α 
protein as expected; however, Caki-1 cells although classified as metastatic ccRCC and reported to 
be harboring wild-type VHL, did not express HIF-1α protein in our study.  
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Figure 4. Metformin inhibited cell migration and invasion in both Caki-1 and Caki-2 cells. In vitro
scratch migration assay at 0, 6 and 24 h following metformin treatment (5, 10, 20, and 50 mM) are shown
in (A) Caki-1 cells (B) and Caki-2 cells. Images are representative of three independent experiments
in each group. Pooled quantified normalized data expressed as gap reduction (percentage of control)
is presented for (C) Caki-1 and (D) Caki-2. (E) Western blot analysis of the expression of α-SMA in
Caki-1 and Caki-2. Images are representative of n = 4–5 per group. (F) Histograms represent pooled
densitometry data normalized to β-actin expressed as the percentage of control. Data are presented as
mean ± SEM. * P < 0.05 vs. control.
3.5. Metformin Represses Hypoxia-Inducible Factor-1α Protein
The overexpression of HIF-1α protein has been shown to be involved in the development and
progression of ccRCC due to mutations i the VHL gene [28]. Therefore, targeting HIF-1α protein might
be a promising approach. T investigate wh ther metformin could affect th re sion of HIF-1α,
Western blot a alysis was performed in both cell lines i t absence and pres nce of metformin
(2, 5, and 10 mM). Intriguingly, as shown in Figure 5A,B, there was no expression of HIF-1α protein
with Caki-1 cells; however, Caki-2 cells expressed HIF-1α protein. Importantly, in the presence of
metformin (10 mM), the protein expression of HIF-1α was reduced in Caki-2 cells compared to the
control (Figure 5A). In addition, we also evaluated the expression of HIF-2α protein (data not shown);
however, we did not observe any expression of this protein in both cell lines. These results showed that
Caki-2 cells, which are known to express wild-type pVHL, expressed high levels of HIF-1α protein as
expected; h wever, Caki-1 cells although cla sified as metastatic ccRCC and reported to be harboring
wild-type VHL, did not express HIF-1α protein in our study.
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Figure 5. Metformin reduced the expression of HIF-1α in Caki-2 renal cancer cells. (A) Shows a Western
blot analysis of HIF-1α in Caki-1 and Caki-2 cells incubated in the absence (control) or presence of
metformin (2, 5, and 10 mM). Images are representative of three independent experiments per group.
(B) Histograms represent pooled densitometry data normalized to β-actin expressed as the percentage
of control. Data are presented as mean ± SEM.
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3.6. Metformin Treatment Causes AMPK Activation and Inhibition of Akt/mTOR Axis in ccRCC Cell Lines
It is well-documented that AMPK is a cellular metabolic protein that has been connected to the
PI3K/Akt/mTOR signaling axis, and the latter is involved in various cellular signaling pathways that
are vital for cell growth and differentiation [37,38]. As Metformin is a known AMPK activator, we
investigated the effect of metformin treatment on AMPK and the Akt/mTOR signaling pathway in
Caki cell lines.
As expected, treatment with metformin induced a dose-dependent activation of AMPK in both
Caki-1 and Caki-2 cells in comparison to the control, as shown in Figure 6A,B. Significant activation of
AMPK was observed with metformin at 5 mM (166%) and 10 mM (172%) in Caki-2; however, Caki-1
cells exhibited a significant activation of AMPK only with the highest dose of metformin (10 mM
(138%)), as shown in Figure 6B. On the other hand, as depicted in Figure 6C,D, our results also revealed
a dose-dependent reduction of Akt phosphorylation in both cell lines in the presence of metformin,
with the most prominent effect observed at the concentration of 10 mM of metformin. Furthermore,
significant repression of mTOR phosphorylation was observed in a dose-dependent manner in both
cell lines; however, Caki-2 cells were more sensitive in comparison with Caki-1 cells to the effect of
metformin as shown in Figure 6E,F. These findings suggest that the antineoplastic effect of metformin
is associated with the activation of AMPK, which negatively regulates mTOR, a key mediator in the
PI3K/Akt signaling pathway. In addition, we investigated if the effect of metformin was dependent or
independent of PTEN protein, which is a natural inhibitor of the PI3K/Akt pathway [39]. Our results
revealed that the metformin-induced suppression of PTEN phosphorylation was more prominent in
Caki-1 cells compared to Caki-2 cells as shown in Figure 6G,H.
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Figure 6. etfor in activated A PK and reduced the activation of the Akt/ TOR axis in both Caki-1
and Caki-2 renal cancer cells. Western blot analyses are shown for (A,B) p-AMPK (Thr172), (C,D) p-Akt
(Ser473), (E,F) p-mTOR (Ser2448), and (G,H) PTEN (Ser380) in Caki-1 and Caki-2 cells incubated
in the absence (control) or presence of metformin (2, 5, and 10 mM). Images are representative of
three independent experiments per group. (B,D,F,H) Histograms represent pooled densitometry data
normalized to β-actin expressed as the percentage of control. Data are presented as mean ± SEM.
* P < 0.05; ** P < 0.001; and *** P < .0001 vs. control.
3.7. etformin Reduces the Expression of Autophagy-Related Protein LC3
It is ell-kno n that at the olecular level, autophagy regulates various cell death and survival
signaling path ays that can, in turn, decide the fate of tu or cells [16,40]. oreover, studies have
sho n that T R negatively regulates autophagy in cancer cells [40]. ence, one could expect an
induction of autophagy process in the presence of metformin; however, surprisingly in our study,
metformin failed to induce the expression LC3-II, a key marker of autophagy, in both Caki-1 and
Caki-2 cells (Figure 7A,B). Instead, a paradoxical response with a low level of expression of LC3-II
autophagic marker was observed in both cell lines, as shown in Figure 7A,B. Autophagy inhibition was
further confirmed by flow cytometry analysis using a Cyto-ID® kit where a significant inhibition of
autophagic flux was observed in both Caki-1 and Caki-2 cells in the presence of metformin compared
to controls (Figure 7C,D).
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3.8. Metformin Decreases the Expression of β-Catenin, an Important Regulator of the Canonical Wnt 
Signaling Pathway 
The canonical Wnt/β-catenin signaling pathway plays a critical role in various cellular and 
developmental processes, and its aberrant activation has been linked with some cancers including 
ccRCC [41]. Studies in ccRCC cell lines such as A-498, A704, and Caki-2 cells revealed a constitutive 
activation of the Wnt/β-catenin pathway with upregulation of β-catenin, which contributes to 
promoting excessive cell proliferation and differentiation [42]. Subsequently, targeting the Wnt/β-
catenin signaling pathway might be a potential strategy to treat renal cancer. Thus, we evaluated here 
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Figure 7. Metformin blunted autophagy induction in both Caki-1 and Caki-2 renal cancer cells.
(A) Western blot analysis of LC3-II in Caki-1 and Caki-2 cells incubated in the absence (control) or
presence of metformin (2, 5 and 10 mM). Images are representative of three independent experiments
per group. (B) Histograms represent pooled densitometry data normalized to β-actin expressed as the
percentage of control. Data are presented as mean ± SEM. Results of autophagy assessment by flow
cytometry analysis using a Cyto-ID® are shown for (C) Caki-1 and (D) Caki-2 cells. (C,D) Histograms
represent pooled data from three independent experiments per group. Data are presented as
mean ± SEM. * P < 0.05; ** P < 0.001; and *** P < 0.0001 vs. control.
3.8. Metformin Decreases the Expression of β-Catenin, an Important Regulator of the Canonical Wnt
Signaling Pathway
The canonical Wnt/β-catenin signaling pathway plays a critical role in various cellular and
developmental processes, and its aberrant activation has been linked with some cancers including
ccRCC [41]. Studies in ccRCC cell lines such as A-498, A704, and Caki-2 cells revealed a constitutive
activation of the Wnt/β-catenin pathway with upregulation of β-catenin, which contributes
to promoting excessive cell proliferation and differentiation [42]. Subsequently, targeting the
Wnt/β-catenin signaling pathway might be a potential strategy to treat renal cancer. Thus, we
evaluated here the impact of metformin treatment on the Wnt/β-catenin pathway. Our results showed
a dose-dependent decrease in the protein levels of Wnt3a (Figure 8A,B), phospho-LRP6 (Figure 8C,D),
and phospho-β-catenin (Figure 8G,H), in the presence of metformin in both Caki-1 and Caki-2 cells.
However, the inhibition of this pathway was more pronounced in Caki-2 cells compared with Caki-1
cells. Together, these results further suggest that Caki-2 cells are more sensitive to metformin treatment
compared to Caki-1 cells (Figure 8).
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Figure 8. Metformin inhibited Wnt/β-catenin signaling in both Caki-1 and Caki-2 renal cancer cells. 
Western blot analyses are shown for (A,B) Wnt3a, (C,D) p-LRP6 (Ser1490), (E,F) GSK-3β (Ser9) and 
(G,H) p-β-catenin (Ser33/37/Thr41) protein in Caki-1 and Caki-2 cells incubated in the absence 
(control) or presence of metformin (2, 5, and 10 mM). Images are representative of three independent 
experiments per group. (B,D,F,H) Histograms represent pooled densitometry data normalized to β-
actin expressed as the percentage of control. Data are presented as mean ± SEM. *P < 0.05; **P < 0.001; 
and ***P < 0.0001 vs. control. 
4. Discussion 
In the current study, we investigated the potential anticancer activity of metformin against 
human ccRCC cell lines, Caki-1 and Caki-2. In addition, we examined the possible signal transduction 
mechanisms through which metformin could exert its antineoplastic effects against ccRCC. There is 
an increasing body of evidence that metformin can inhibit cell proliferation and differentiation in 
various types of cancers such as cancers of the lung, prostate, liver, and pancreas [43–46]. Consistent 
with these previous studies, our findings demonstrated that metformin was capable of blunting cell 
growth in both Caki-1 and Caki-2 cells. However, a significant and dose-dependent response to 
metformin treatment was observed with Caki-2 cells in comparison with Caki-1 cells, with Caki-2 
being more sensitive, indicating a difference in sensitivity between the two cell lines toward the action 
of metformin. Consistent with our observations, Kalogirou et al. [29] demonstrated that Caki-1 cells 
were less sensitive towards metformin treatment. Furthermore, Zhang et al. [47] reported that 
metformin decreased the cell viability of Caki-2 and 786-O cells in a dose-dependent manner. 
Additionally, Zhong et al. [48] also observed that metformin inhibited the proliferation of 786-O renal 
cancer cells. 
Cell cycle analysis showed that metformin treatment caused G0/G1 cell cycle arrest in both Caki-
1 and Caki-2 cells compared to controls. However, our data showed a strong and significant dose-
dependent G0/G1 phase arrest in Caki-2 cells in comparison with Caki-1 cells. Consistent with our 
findings, Liu et al. [3] demonstrated that metformin induced G0/G1 cell cycle arrest in Caki-2 and 
786-O cells. Similarly, Xie et al. [49] reported that metformin produced G0/G1 phase arrest in human 
renal cell carcinoma cell line ACHN. To correlate cell cycle results and apoptosis, we assessed the 
apoptotic effect of metformin because in some cases cell cycle arrest may not necessarily be followed 
by cell death or apoptosis. Our findings showed that metformin failed to induce cytotoxicity in Caki-
1 cells, while a significant cytotoxic effect was observed with Caki-2 cells, indicating a differential 
sensitivity of the two cell lines towards metformin. A study by Zhong et al. [48] revealed that 
metformin induces cell death in 786-O renal cancer cells under conditions of low nutritional status, 
which taken together with our results indicate a differential sensitivity of ccRCC cells to metformin, 
adding to the heterogeneity of this cancer. 
It is well-known that cell migration and invasion play a crucial role in the metastasis of cancer 
cells. Our results from the scratch migration study indicated that metformin inhibited cell migration 
of both ccRCC cell lines used. Furthermore, the Western blot analysis results revealed dose-
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or presence of metformin (2, 5, and 10 mM). Images are representativ of thre indep ndent xperim ts
per group. (B,D,F,H) Histograms represent pooled densitometry data normalized to β- ctin expressed
as the percentag of control. Da are presented as mean ± SEM. * P < 0.05; ** P < 0.001; and *** P <
0.0001 vs. control.
4. Discussion
In the current study, we investigated the potential anticancer activity of metformin against human
ccRCC cell lines, Caki-1 and Caki-2. In addition, we examined the possible signal transduction
mechanisms through which metformin could exert its antineoplastic effects against ccRCC. There is
an increasing body of evidence that metformin can inhibit cell proliferation and differentiation in
various types of cancers such as cancers of the lung, prostate, liver, and pancreas [43–46]. Consistent
with these previous studies, our findings demonstrated that metformin was capable of blunting
cell growth in both Caki-1 and Caki-2 cells. However, a significant and dose-dependent response to
metformin treatment was observed with Caki-2 cells in comparison with Caki-1 cells, with Caki-2 being
more sensitive, indicating a difference in sensitivity between the two cell lines toward the action of
metformin. Consistent with our observations, Kalogirou et al. [29] demonstrated that Caki-1 cells were
less sensitive towards metformin treatment. Furthermore, Zhang et al. [47] reported that metformin
decreased the cell viability of Caki-2 and 786-O cells in a dose-dependent manner. Additionally,
Zhong et al. [48] also observed that metformin inhibited the proliferation of 786-O renal cancer cells.
Cell cycle analysis showed that metformin treatment caused G0/G1 cell cycle arrest in both
Caki-1 and Caki-2 cells compared to controls. However, our data showed a strong and significant
dose-dependent G0/G1 phase arrest in Caki-2 cells in comparison with Caki-1 cells. Consistent with
our findings, Liu et al. [3] demonstrated that metformin induced G0/G1 cell cycle arrest in Caki-2 and
786-O cells. Similarly, Xie et al. [49] reported that metformin produced G0/G1 phase arrest in human
renal cell carcinoma cell line ACHN. To correlate cell cycle results and apoptosis, we assessed the
apoptotic effect of metformin because in some cases cell cycle arrest may not necessarily be followed by
cell death or apoptosis. Our findings showed that metformin failed to induce cytotoxicity in Caki-1 cells,
while a significant cytotoxic effect was observed with Caki-2 cells, indicating a differential sensitivity of
the two cell lines towards metformin. A study by Zhong et al. [48] revealed that metformin induces cell
death in 786-O renal cancer cells under conditions of low nutritional status, which taken together with
our results indicate a differential sensitivity of ccRCC cells to metformin, adding to the heterogeneity
of this cancer.
It is well-known that cell migration and invasion play a crucial role in the metastasis of cancer
cells. Our results from the scratch migration study indicated that metformin inhibited cell migration of
both ccRCC cell lines used. Furthermore, the Western blot analysis results revealed dose-dependent
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repression of α-SMA protein expression, further supporting the antimigratory effect of metformin in
ccRCC cell lines (Caki-1 and Caki-2).
To explore the underlying molecular mechanism(s) involved in the antineoplastic effects of
metformin in Caki-1 and Caki-2 cell lines, we investigated the impact of metformin treatment on
various crucial signaling pathways involved in the progression of ccRCC: HIF-1α, AMPK, Akt/mTOR
and Wnt/β-catenin pathways. It is well-documented that the mutation of the VHL tumor suppressor
gene promotes the constitutive activation of HIF-1α and HIF-2α subunits in RCC [17]. Intriguingly, our
study demonstrated two critical differences between Caki-1 and Caki-2 cells. Firstly, although there
are close similarities between the two isoforms of HIF-α, only HIF-1α was constitutively expressed
in Caki-1 and Caki-2 cells. Secondly, our results showed that the expression of HIF-1α protein was
predominantly higher in Caki-2 cells compared to Caki-1 cells and that metformin treatment (10 mM)
caused significant repression of its expression compared to the control. Consistent with our findings,
Raval et al. [17] observed contrasting properties of HIF-1α and HIF-2α on the growth of 786-O cells in
tumor xenografts.
There has been increasing evidence interconnecting the significance of cancer and metabolism.
Cancer cells need to continually synthesize new proteins to support their rapid rate of proliferation and
differentiation, ultimately causing an imbalance in the cellular energy levels, which can be detected by
AMPK [50,51]. Therefore, targeting AMPK might be an effective approach to treat cancer, either alone
or in combination. In the present study, as expected, metformin upregulated the phosphorylation of
AMPK in both Caki-1 and Caki-2 cells. However, Caki-2 cells expressed higher levels of phosphorylated
AMPK compared to Caki-1 cells. AMPK has been linked to other essential pathways implicated in cell
growth like the PI3K/Akt/mTOR axis, which was found to be activated in ccRCC [52]. Notably, by
activating AMPK, metformin decreased the phosphorylation and subsequently the activation of both
Akt and mTOR in both Caki-1 and Caki-2 cells. Interestingly, metformin reduced the phosphorylation
of mTOR more strongly in Caki-2 cells compared to Caki-1, which correlates with a higher level of
phosphorylated AMPK observed with Caki-2 cells. Liu et al. [3] confirmed in a study that metformin
induced the activation of AMPK and inhibited mTOR activation in 786-O and OS-RC-2 ccRCC cell lines.
In addition, Liu et al. [3] has shown, in a murine xenograft model, that daily treatment of mice with
metformin prevented ccRCC tumor growth. Although many previous studies have demonstrated the
significance of mTOR as an essential negative regulator of autophagy induction [53], to our surprise,
our results were contrasting in both Caki-1 and Caki-2 cells as metformin caused a significant inhibition
of autophagy (measured using LC3-II levels) compared to a control. It is reasonable to speculate that
metformin may have caused this paradoxical effect on autophagy through an AMPK-independent
mechanism. Depending on the dose and duration of treatment, metformin was found to act via
both AMPK-dependent and AMPK-independent mechanisms [54]. Inhibition of autophagy has
been reported in other studies to also contribute to cancer cell death in ccRCC [55]. For instance,
Singla et al. [56] explored the effect of combining temsirolimus (mTOR inhibitor) and chloroquine
(autophagy inhibitor) to ameliorate anticancer activity against ccRCC in EMT-transformed metastatic
cells. Moreover, emergent evidence indicates that in a nutrient-limited microenvironment, autophagy
can promote tumor growth [57,58]. Thus, inhibition of autophagy is regarded as an effective strategy
to suppress tumor progression in certain cancers. Taken together with our findings, inhibition of
autophagy might represent a potential mechanism by which metformin elicits its antineoplastic effects
against ccRCC.
Besides VHL mutation with subsequent overactivation of HIF-1α and mTOR signaling pathways,
other signaling pathways may also play a vital role in the development and progression of ccRCC.
Of particular interest, Wnt/β-catenin pathway and its dysregulation with subsequent overactivation
of β-catenin have been implicated in ccRCC pathogenesis [42,59]. Therefore, the inhibition of
Wnt/β-catenin signaling pathway might emerge as a novel alternative therapeutic target to suppress
ccRCC progression. Interestingly, our current study revealed that the metformin-treated cells exhibited
a lower level of expression of major modulators of the Wnt/β-catenin pathway including β-catenin
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in both Caki-1 and Caki-2 cell lines compared to controls, which may, in turn, contribute to the
antineoplastic effects of metformin in ccRCC.
5. Conclusions
Our findings demonstrate that metformin may be a potential drug of choice in the treatment of
ccRCC. Differential responses were observed between the two cell lines studied, with Caki-2 cells
being more sensitive to metformin compared with Caki-1 cells, indicating the complexity of this
cancer. The discrepancy in sensitivity to metformin between the two cell types could be linked to
the differential expression of HIF-1α despite that both cell lines were reported to carry a wild-type
VHL. Furthermore, we highlighted here that antineoplastic effects of metformin against ccRCC are,
at least partly, based on its ability to activate AMPK and the subsequent inhibition of Akt/mTOR axis
in addition to a focal effect on the inhibition of the Wnt/β-catenin pathway. Nevertheless, our data do
not rule out other AMPK-independent mechanisms. Because of the heterogeneity of ccRCC and the
molecular differences between its subtypes, additional studies are warranted to further harness the
potential use of metformin as an antitumor agent in ccRCC.
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